Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma

Schlapbach, Christoph; Yerly, Daniel; Daubner, Barbara; Yawalkar, Nikhil; Hunger, Robert E (2011). Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma. Journal of dermatological science, 62(2), pp. 75-83. Amsterdam: Elsevier 10.1016/j.jdermsci.2011.02.001

Full text not available from this repository. (Request a copy)

There is currently no curative therapy for cutaneous T cell lymphoma (CTCL). New therapies are therefore needed. Telomerase, the enzyme that allows for unrestricted cell divisions of cancer cells, is a promising target for cancer therapy. The telomerase-specific peptide vaccination GV1001 has shown promising results in previous studies. Since telomerase is expressed in malignant cells of CTCL, GV1001 vaccination in CTCL is a promising new therapeutic approach.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Schlapbach, Christoph; Yerly, Daniel; Yawalkar, Nikhil and Hunger, Robert

ISSN:

0923-1811

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:21

Last Modified:

06 Dec 2013 13:27

Publisher DOI:

10.1016/j.jdermsci.2011.02.001

PubMed ID:

21377838

Web of Science ID:

000290645300001

URI:

https://boris.unibe.ch/id/eprint/7072 (FactScience: 212222)

Actions (login required)

Edit item Edit item
Provide Feedback